80 results
Page 4 of 4
8-K
EX-99.1
lvpxz
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
75g1cp7sl73f
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
ctb m3mjaj
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.2
k48896ly10pdpq7 hd2v
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
EX-99.1
uif0rv093ompm0vz
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
ktltwsuvudf
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
424B5
75e9bl
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
rw3afylj77425
4 Oct 19
Shelf registration
4:06pm
8-K
EX-99.1
epwp atwu3tgk2j
14 Aug 19
Sutro Biopharma Reports Second Quarter 2019 Financial Results
12:00am
8-K
EX-99.1
vzyxb
15 May 19
Sutro Biopharma Reports First Quarter 2019 Financial Results
7:00am
8-K
EX-99.1
9dizi6lsfudftlz49
1 Apr 19
Sutro Biopharma Reports Full Year 2018 Financial Results
10:22am
10-K
kn348 7haxc49xu
1 Apr 19
Annual report
12:00am
8-K
EX-99.1
3ea2 e74d4f3
15 Nov 18
Sutro Biopharma Reports Third Quarter 2018 Financial Results
12:00am
10-Q
vb0lqd
14 Nov 18
Quarterly report
12:00am
DRS/A
p97hmpbi
10 Jul 18
Draft registration statement (amended)
12:00am
DRS
r7pn2
1 Jun 18
Draft registration statement
12:00am